Anchored in work licensed from University of Louisville, Advanced Cancer Therapeutics (ACT) is a biotechnology company tackling discovery and early development of cancer therapeutics with commercialization and manufacturing of the most promising discoveries. The firm is developing a pipeline of anti-cancer products, including MIF, a macrophage migration inhibitory factor; PU27, a synthetic oligonucleotide that is used as an anticancer compound; PFKFB3, a small molecule compound; CK37, a small molecule that inhibits cell proliferation, choline kinase enzymatic activity, and tumor growth; and a vaccine for human papilloma virus, which is caused for cervical cancer. The firm obtained exclusive licenses to four anti-cancer therapeutics and one pharmaceutical vaccine for human papillomavirus (HPV), all derived from tobacco plants. This may provide patients broad protection against many strains of HPV, as well as provide a cost-effective alternative to existing HPV vaccines on the market today. In 2017 it was loally reported that the results of important trials were disappoiting andmya have resulted in a wind down of the firm's operations
